NRX Pharmaceuticals, Inc. 8-K

What Happened NRX Pharmaceuticals, Inc. announced that its newly formed Florida R&D subsidiary, NRx Defense Systems, Inc. (NRXD), received a July 21, 2026 letter from DARPA’s Defense Sciences Office notifying the company that NRXD’s SPARC‑TMS clinical trial proposal was selected for negotiation of a potential award. The SPARC‑TMS protocol — a phase 2/3 trial approved by the FDA and posted on ClinicalTrials.gov (NCT07227103) — tests robotic‑enabled Transcranial Magnetic Stimulation (TMS) combined with NRX‑101 (a patented D‑cycloserine/lurasidone product) to evaluate remission from depression.

Key Details

• NRXD was incorporated in April 2026 as a Florida-based R&D subsidiary to develop neuroplastic treatments combining D‑cycloserine with TMS.
• DARPA selection date: July 21, 2026; selection is for negotiation only and is not a notice of award or authorization to incur costs.
• Trial protocol: FDA‑approved phase 2/3; posted at ClinicalTrials.gov (NCT07227103); trial name: Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC‑TMS).
• Planned sites: Harvard/McLean Hospital, clinics operated by HOPE Therapeutics, and designated military treatment facilities including Walter Reed National Military Medical Center. NRX‑101 holds company patents and previously received FDA Breakthrough Therapy Designation.

Why It Matters This filing shows NRX is pursuing government‑sponsored research funding through a DARPA negotiation for a potentially high‑visibility clinical trial combining its patented drug candidate with advanced TMS delivery. For investors, DARPA selection for negotiation is a positive development in validating the program and expanding potential funding and clinical partnerships, but it is not a guaranteed contract or revenue until definitive award terms are negotiated and signed.